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A B S T R A C T
Influenza A virus carries eight negative single-stranded RNAs and uses spliced mRNAs to increase the number of
proteins produced from them. Several genome-wide screens for essential host factors for influenza A virus re-
plication revealed a necessity for splicing and splicing-related factors, including Cdc-like kinase 1 (CLK1). This
CLK family kinase plays a role in alternative splicing regulation through phosphorylation of serine-arginine rich
(SR) proteins. To examine the influence that modulation of splicing regulation has on influenza infection, we
analyzed the effect of CLK1 knockdown and inhibition. CLK1 knockdown in A549 cells reduced influenza A/
WSN/33 virus replication and increased the level of splicing of segment 7, which encodes the viral M1 and M2
proteins. CLK1−/− mice infected with influenza A/England/195/2009 (H1N1pdm09) virus supported lower
levels of virus replication than wild-type mice. Screening of newly developed CLK inhibitors revealed several
compounds that have an effect on the level of splicing of influenza A gene segment M in different models and
decrease influenza A/WSN/33 virus replication in A549 cells. The promising inhibitor KH-CB19, an indole-based
enaminonitrile with unique binding mode for CLK1, and its even more selective analogue NIH39 showed high
specificity towards CLK1 and had a similar effect on influenza mRNA splicing regulation. Taken together, our
findings indicate that targeting host factors that regulate splicing of influenza mRNAs may represent a novel
therapeutic approach.
1. Introduction
The process of alternative splicing diversifies gene expression, with
75% of human genes having at least two alternatively spliced isoforms.
Splicing is highly regulated via recognition of sites by different proteins
and synergistic effects of multiple weak binary-interactions
(Schellenberg et al., 2008; Wahl et al., 2009). Several viruses also
employ alternative splicing to code for diverse proteins from their small
genomes (Fukuhara et al., 2006; Hryckiewicz et al., 2011; Johansson
and Schwartz, 2013; Ortı;́n, 1998). Influenza A virus (IAV) makes use of
this process to generate several of its proteins (Lamb and Lai, 1980;
Lamb et al., 1981; Wise et al., 2012). It belongs to the family of Or-
thomyxoviridae and carries a genome consisting of eight negative single-
stranded viral RNAs (vRNAs). According to current knowledge, the HA,
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NP (nucleoprotein) and NA segments each encode only one viral pro-
tein, while the PB1, PB2, PA, M and NS segments give rise to two or
more mRNAs via alternative reading frame, differential initiation at
AUG codons, ribosomal frameshifting or splicing (Chen et al., 2001;
Jagger et al., 2012; Lamb and Lai, 1980; Lamb et al., 1981; Wise et al.,
2009, 2012). The unspliced M mRNA encodes for M1 matrix protein
while the spliced M2 mRNA encodes the M2 ion-channel protein (Inglis
and Brown, 1981; Lamb et al., 1981). A third splice variant, M3 mRNA,
is not required for replication of influenza virus in vitro (Jackson and
Lamb, 2008) and it remains unclear if any protein is expressed from it.
The M4 mRNA uses the 5′ splice site (ss) at position 146 and exists only
in some strains, such as A/WSN/33 (Shih et al., 1998). Mutation at the
5'ss of M4 mRNA impairs M mRNA splicing and virus growth via an
unclear mechanism (Chiang et al., 2008). An M2-related protein named
M42 is expressed from M4 mRNA utilizing an alternative start codon
and is hypothesized to replace the function of M2 (Wise et al., 2012).
The NS segment also undergoes splicing, with the unspliced mRNA
encoding the non-structural protein NS1, while the spliced mRNA en-
codes the nuclear export protein NS2/NEP (Lamb and Lai, 1980). Re-
cently, the PB2 segment has also been shown to produce a spliced
mRNA that encodes PB2-S1, which, like the unspliced PB2, inhibits
RIG-I-dependent IFN signaling (Yamayoshi et al., 2015).
Viral mRNA splicing utilizes the cellular splicing machinery and is
tightly regulated to maintain adequate expression of the unspliced
mRNA. Several mechanisms have so far been found for this: The cellular
splicing factor SF2/ASF binds to a purine-rich splicing enhancer se-
quence at the 3’ exon of M1 mRNA to control production of M2 mRNA
and protein synthesis (Shih and Krug, 1996). NS1 protein regulates
splicing of its own mRNA (Garaigorta and Ortin, 2007), as well as
splicing and export of M mRNA (Robb and Fodor, 2012). The cellular
protein NS1-BP, which binds influenza NS1 protein, also promotes pre-
mRNA splicing (Wolff et al., 1998). In addition, the rate of NS1 mRNA
splicing is controlled by cis-acting sequences of the mRNA itself as well
as nucleocytoplasmic transport of the unspliced mRNA (Alonso-Caplen
and Krug, 1991). A recent report elucidated a similar cis-acting reg-
ulatory element in NS mRNA that is an exonic splice enhancer, which
utilizes the NS1 protein itself and the host factor SF2 (Huang et al.,
2017).
Previous genome-wide RNAi screens have identified CLK1 as a host
cell factor required for influenza A virus replication (Karlas et al., 2010;
Konig et al., 2010). CLK1 belongs to the family of human protein ki-
nases, which has high homology to the yeast cdc2/CDC28 kinases
(Johnson and Smith, 1991). There are four isoforms of CLK in mam-
mals, CLK1, 2, 3 and 4 (Hanes et al., 1994; Nayler et al., 1997). CLK1
phosphorylates the C-terminus of SR proteins, a family of splicing fac-
tors, to regulate their subcellular distribution and activity (Colwill
et al., 1996; Duncan et al., 1997; Ngo et al., 2005). Overexpression of
CLK1 is known to promote use of the distal 5'ss of the adenoviral E1A
gene (Duncan et al., 1997). Similarly, processing of HIV mRNA is af-
fected by overexpression of CLK isoforms (Wong et al., 2011), while
inhibition of the SR protein-specific kinases SRPK1 and 2 (Ngo et al.,
2008) leads to reduced HIV production (Fukuhara et al., 2006). Dif-
ferent inhibitors of CLK1 can reduce HIV replication in vitro via effects
on mRNA processing, with the notable caveat that specificity for dif-
ferent CLK isoforms appears to have a large influence on the effec-
tiveness (Wong et al., 2011, 2013). In the same way, we have pre-
viously found that the CLK inhibitor TG003 alters IAV M mRNA splicing
and M protein expression in vitro (Karlas et al., 2010).
Here, we describe that inhibiting CLKs in host cells with small
molecule inhibitors impaired IAV replication. The degree to which
splicing was altered and the extent to which replication was inhibited
was dependent on the specificity of the CLK inhibitor. Assessment of the
downstream targets of CLK family kinases identified SRSF3 as the main
SR protein which affects mRNA splicing and IAV replication. We con-
clude that proper viral mRNA splicing is required for efficient replica-
tion of IAV.
2. Materials and methods
2.1. Cell lines and viruses
Human lung epithelial cells (A549, CCL-185, ATCC-LGC) were
cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco) sup-
plemented with 10% fetal calf serum (FCS, Biochrome), 4mM L-glu-
tamine and 4mM sodium pyruvate at 37 °C and 5% CO2. Madin–Darby
canine kidney cells (MDCK, CCL-34, ATCC-LGC) were grown in DMEM
supplemented with 10% fetal calf serum, 4mM L-glutamine and 100 U/
ml penicillin/streptomycin at 37 °C and 5% CO2. Influenza virus A/
WSN/33 and A/England/195/2009 virus was propagated in allantoic
fluid of eleven-day old embryonated chicken eggs as previously de-
scribed (Szretter et al., 2006). The recombinant wild-type virus A/
Victoria/3/75 (H3N2) was generated by reverse genetics, as described
previously (Elleman and Barclay, 2004; Neumann et al., 1999; Roberts
et al., 2011). The titer of virus stocks was determined by plaque assay
on MDCK cells using agar overlay medium (Szretter et al., 2006).
2.2. Chemical inhibitor treatment in eukaryotic cells
Chemical inhibitor was diluted to the specified concentration in
culture medium, added to A549 cells and incubated at 37 °C with 5%
CO2 for 2 h. DMSO diluted in culture medium at the same volume as the
inhibitor served as control. After 2 h, cells were infected with influenza
virus A/WSN/33 diluted in infection buffer at the specified MOI and
incubated at room temperature for 1 h. Virus was then removed, re-
placed with infection medium containing the chemical inhibitor or
DMSO at the specified concentration and incubated at 37 °C with 5%
CO2. TG003 was purchased from Sigma.
2.3. CRISPR/Cas9-mediated CLK1 knockout cells
A549 cells lacking a functional CLK1 gene were generated as de-
scribed (Karlas et al., 2016). Briefly, Cas9-expressing A549 cells were
generated by transducing with lentiviruses based on the plasmid len-
tiCas9-Blast (Addgene number 52962), followed by selection with
blasticidin. Cells were then transduced with lentivirus derived from the
plasmid lentiGuide-Puro44 (Addgene number 52963), which leads to
the expression of CLK1-specific gRNAs.
2.4. SC35 subnuclear distribution detection upon CLK overexpression and
inhibitor treatment
A549 cells were transfected with plasmid expressing GFP-tagged
mCLK1, mCLK2, mCLK3 and mCLK4 using Lipofectamine LTX
(Invitrogen) according to manufacturer's instruction. The plasmids ex-
pressing GFP-tagged mCLKs were a kind gift from Alan Cochrane
(University of Toronto, Canada). At 16 h post-transfection, cells were
treated with 50 μM TG003, 12.5 μM NIH39 or 50 μM kH-CB19 for 6 h,
washed once with PBS and fixed with 4% paraformaldehyde. Cells were
permeabilized with 1% Triton X-100, followed by blocking in 1xPBS
containing 1% BSA/0.5% gelatine. Subnuclear distribution of SC35 was
detected by labelling with mouse anti-SC35 antibody (BD Science)
followed by Cy3-labelled anti-mouse IgG (Jackson Immuno Research
Lab) and Hoechst, as described above. Images were captured using a
Leica DMR microscope.
2.5. Luciferase splicing assay
To quantify influenza segment M splicing, a cell-based influenza-
driven splicing assay that monitors expression of the three mRNAs
produced from the M gene (M1, M2 and M3) was used (Moncorgé O.
and Barclay W., in preparation). Briefly, plasmids that generate in situ
viral-like RNAs that can be amplified and expressed by influenza virus
polymerase are transfected in 293T cells 24 h prior to viral infection.
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The viral-like RNAs are based on segment M sequence (A/England/
195/2009, H1N1pdm09) and retain all the documented control regions
potentially involved in splicing (Lamb and Lai, 1982; Moss et al., 2011,
2012; Shih and Krug, 1996). Instead of encoding the authentic virus
products, the reporter RNAs encode luciferase proteins in frame with
the M1 (unspliced), M2 (spliced) or M3 (spliced) mRNA open reading
frames. This allows quantification of expression of proteins that arise
from the various alternative splicing routes by a dual luciferase assay on
lysates of infected cells. 24 h post-infection (MOI 1), cells are lysed
using 5x passive lysis buffer (Promega) and luciferase activity is mea-
sured.
2.6. LabChip kinase screening
Enzymatic kinase screening was carried out using the Caliper mo-
bility shift assay, which is based on the difference in capillary electro-
phoresis mobility of a fluorescently tagged peptide as a result of the
addition of a phosphate moiety by the studied kinase. The consensus
peptide for CLK1 (AFRREWSPGKEAKK) was solubilized at 10mM in
DMSO and used as a substrate at a final concentration of 1 μM and the
CLK1 enzyme at 0.945 ng in each reaction in 30 μl volumes. 0.3 μl each
of compound solution (1mM in DMSO) was added to 10 μl assay buffer
(50mM HEPES [pH 7.5], 80mM NaCl, 600 μM MgCl2, 1 mM DTT,
0.002% Tween 20). After addition of 10 μl CLK1 in assay buffer, the
reaction was started by adding 10 μl of substrate solution with con-
sensus peptide and ATP at concentrations set to the KM for CLK1 at
19.2 μM. After incubation for 120min at 20 °C 50 μl stop solution was
added (100mM HEPES [pH 7.5], 5% DMSO, 0.1% coating reagent
[Caliper Lifescience] 10mM EDTA [pH 8.0], 0.015% BRIJ35) and re-
actions analyzed in a LC3000 reader (Caliper Life Sciences) using the
following settings: DS -600, US -2300, base pressure – 0.5, screen
pressure – 1.8, plate cycles 1, end of plate delay 60, final delay 30,
sample time 0.2, post sample buffer time 35, dye time 0.2, post-dye
buffer time 40. Validation of dosage-dependent inhibitory activity was
carried out by IC50 determinations in serial 1:1 dilutions from 50 μM to
50 nM in ten steps and in duplicate. For automated data analysis, the
LabChip files are converted to a standardized output format (in-house
developed software) and fed into statistical analysis by the open source
software R and KNIME to generate exact curve fittings and IC50 calcu-
lations.
2.7. Animal experiments
Animals were housed and bred under pathogen-free conditions, in a
BSL 2 laboratory according to the German Animal Protection Law
(Tierschutzgesetz TierSchG). Animal testing was approved by the local
authorities (Landesamt für Gesundheit und Soziales Berlin) under li-
cense G0206/12. C57BL/6/J and CLK1−/− mice were obtained from
Charles River and the European Conditional Mouse Mutagenesis
Program (EUCOMM) Consortium, respectively, and further bred in-
house. C57Bl/6 mice aged 11–16 weeks and weighing 20.9–25.6 g and
CLK1−/− mice aged 7 weeks and weighing 20.4–24.0 g were in-
tranasally infected with 9× 104 PFU of influenza A/England/195/2009
virus in 30 μl infection buffer. Two days later, lungs of infected animals
were isolated and homogenized in PBS, followed by centrifugation at
800×g for 8min at 4 °C. The amount of infectious virus was then
quantified using plaque assay.
3. Results
3.1. CLK1 knockdown reduces influenza A virus replication and regulates
the splicing of viral mRNA
CLK1 was identified as an essential host factor for influenza A virus
infection in two previous screens (Karlas et al., 2010; Konig et al.,
2010). To verify the result, we performed knockdown experiments in
A549 cells to silence kinases that regulate splicing, including the CLK
and SRPK family kinases and the dual specificity tyrosine phosphor-
ylation-regulated kinase 1 (DYRK1A), followed by infection with in-
fluenza A/WSN/33 at MOI 0.01 for 36 h. The infectious viral particles
produced were quantified by reinfection of MDCK cells, followed by
indirect immunofluorescence staining. Among the CLK family kinases,
only knockdown of CLK1 significantly reduced the production of virus
progeny with both siRNAs (Fig. 1A), compared to the negative siRNA
control Allstars. There was also a significant reduction in virus re-
plication after knockdown of SRPK1 and SRPK2 with both siRNAs, al-
beit 10-fold less than that seen with CLK1 (Fig. 1A). Knockdown did not
significantly affect host cell viability at 48 h post-transfection (Fig. S1A)
and most of the siRNAs used for the knockdowns reduced gene ex-
pression efficiently, as quantified by qPCR (Fig. S1B). Due to the strong
similarity between the different CLK isoforms, especially between CLK1
and CLK4, the quantification of knockdown efficacies on protein level is
Fig. 1. CLK1 is an essential host factor for influenza A virus replication.(A)
Replication assay was carried out by infection of A549 cells 48 h post siRNA
transfection with influenza A/WSN/33 at MOI of 0.01 for 36 h. The titer of
infectious viral particles in the supernatant was measured using indirect im-
munofluorescence staining (shown are mean values of three independent
experiments ± SEM). *p-value< 0.05, **p-value<0.01, ***p-value<
0.0001, one-way ANOVA. (B) Cells isolated from the lungs of either C57BL/6
wild-type or Clk1−/− mice were infected with influenza A/WSN/33 at MOI
0.01 for 72 h. Production of infectious viral progeny was measured using in-
direct immunofluorescence staining. *p-value< 0.05, two-tailed unpaired t-
test. (C) C57BL/6 wild-type or Clk1−/− mice (n= 6) were intranasally in-
fected with 9× 104 PFU of influenza A/England/195/2009 (H1N1pdm09). At
48 h after infection, infectious viral particles within the lungs were quantified
using plaque assay. *p-value<0.05, two-tailed unpaired t-test. (D) Validation
of CLK1 as relevant cellular factor. Amount of virus produced in A549 cells
depleted for CLK1 by CRISPR/Cas9 and infected with A/WSN/33 at MOI 0.001
for 24 h. Virus titer was quantified by plaque assay (shown are mean values of
three independent experiments ± SEM).
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not feasible.
To further verify the importance of CLK1 in influenza A virus re-
plication, we isolated cells from the lungs of CLK1−/− and C57BL/6
mice. Equal numbers of isolated cells were infected with influenza A/
WSN/33 at MOI 0.01 for 72 h. Viral replication was significantly re-
duced when compared to control cells isolated from wild-type C57BL/6
mice (Fig. 1B), despite the fact that even in the CLK1−/− cells a slight
expression of CLK1 was detectable (Fig. S1C). To confirm this effect in
vivo, intranasal infection of C57BL/6 and CLK1−/− mice was per-
formed with influenza A/England/195/2009 for two days. Determina-
tion of virus titer in the lungs harvested at 2 days post-infection showed
that the number of infectious viral particles obtained from CLK1−/−
mice was significantly reduced (Fig. 1C). Similarly, A549 cells lacking
CLK1 expression after CRISPR/cas9-mediated knockout replicated in-
fluenza viruses less efficiently than controls (Fig. 1D).
As CLK1 is known to regulate mRNA splicing, we next investigated
whether knockdown has any effect on splicing of influenza mRNAs.
qRT-PCR quantification of spliced and unspliced viral mRNAs upon
infection with A/WSN/33 at MOI 4 for 5 h showed an increased ratio of
spliced to unspliced M mRNA in CLK1 knockdown A549 cells, but no
significant effect on NS mRNA splicing was observed compared to the
negative control Allstars (Fig. 2A). Western blot analysis also showed
that expression of the unspliced viral M1 and NS1 proteins was reduced
upon CLK1 knockdown, but little or no effect on the level of the spliced
M2 protein was observed (Fig. 2B).
3.2. Screening of CLK inhibitors identifies new compounds that inhibit
influenza virus replication
We previously observed that cells treated with the CLK inhibitor
TG003 showed reduced influenza A/WSN/33 virus replication (Karlas
et al., 2010). This prompted us to screen 60 new compounds (structu-
rally related to KH-CB19, previously published as a CLK1 inhibitor
(Fedorov et al., 2011)) targeting CLK family kinases in an IAV re-
plication assay. Several of these compounds inhibited influenza re-
plication to a greater extent than the commercially available TG003
(Fig. 3A), without significantly affecting cell viability at 48 h post-
treatment (Fig. S2). Two of these were selected for further experiments -
NIH39 and KH-CB19, which had IC50 values of 6.6 μM and 13.6 μM for
antiviral activity, respectively (Fig. 3B and C). Treatment of A549 cells
with NIH39 at 6.25 μM or 12.5 μM upon infection with A/WSN/33 at
MOI 4 for 5 h resulted in an increase of the spliced to unspliced viral M
mRNA ratio (Fig. 4A, Fig. S3A). Unexpectedly, however, qRT-PCR
analysis showed that the viral NS mRNA splicing ratio was significantly
reduced when cells were treated with 12.5 μM NIH39 (Fig. 4A, Fig.
S3B). Viral M1, M2 and NS1 protein levels were all found to be
markedly reduced when analyzed by Western blot (Fig. 4B, Fig. S3E). In
contrast to the effects observed with NIH39 treatment, A549 cells
treated with KH-CB19 at 50 μM or 100 μM did not show any effect on
the spliced to unspliced ratio of viral M and NS mRNAs (Fig. 4C, Figs.
S3C–D), although the levels of all three viral proteins were also reduced
(Fig. 4D, Fig. S3F).
It has been reported previously that overexpression of CLK family
kinases alters the subnuclear distribution of the SR protein by altering
its phosphorylation state (Wong et al., 2011, 2013). The observed dif-
ferential effects of the various CLK inhibitors on influenza mRNA spli-
cing raised the question whether they affected the four CLK isoforms
differently. Therefore, we next tested the specificity of the inhibitors by
analysing the nuclear speckle pattern of SC35 (SRSF2) labelling upon
mClk overexpression (Wong et al., 2011). In accordance with the pre-
vious reports, CLK overexpression altered the subnuclear distribution of
SC35 from a speckled to a diffuse pattern (Fig. 5A). Treatment of cells
with TG003 inhibited nuclear speckle disruption by CLK1, 2 and 4
(Fig. 5B). This confirms reports that TG003 inhibits CLK1, CLK4 and to
a lesser extent CLK2 (Muraki et al., 2004; Wong et al., 2011). NIH39
treatment blocked the disruption of nuclear speckles by CLK1 and 4
(Fig. 5C, Fig. S6), while KH-CB19 only inhibited the disruption by CLK4
(Fig. 5D, Fig. S6).
3.3. Identification of the essential SR protein in influenza A virus replication
and its effect on viral mRNA splicing
To identify the downstream targets of CLK1 in influenza infection,
knockdown of SR proteins was performed in A549 cells, followed by
influenza virus replication assay and cell viability analysis. Knockdown
of SRSF3 with each of two siRNAs significantly impaired influenza virus
replication, while the other SRSFs had a less pronounced effect or
showed strong reduction only with one siRNA (Fig. 6A). Host cell via-
bility at 48 h after siRNA transfection was not significantly impaired
upon knockdown of any SRSF proteins (Fig. S4A) and all siRNAs
achieved efficient knockdown (Fig. S4B).
Next, we further analyzed viral mRNA splicing upon SRSF3
knockdown (Fig. S4C). Quantification of spliced and unspliced viral
mRNAs was performed in A549 cells after knockdown, followed by
infection with influenza A/WSN/33 at MOI 4 for 5 h. The result shows
that in the absence of SRSF3 there is an increase in the viral M and NS
mRNA splicing ratios (Fig. 6B, Figs. S4D–E). Remarkably, in-depth
analysis of viral M and NS mRNA sequences using ESEFinder and
SFmap showed different binding sites for several SR proteins between
the M and NS mRNA including binding sites for SRSF3 (Fig. S7). On the
protein level, SRSF3 knockdown slightly reduced the levels of viral M1
and NS1 proteins, as we observed with CLK1, and slightly increased the
level of the spliced M2 protein (Fig. 6C, Fig. S4F). Based on these re-
sults, SRSF3 seems to be the main actor influencing the levels of spliced
viral RNAs upon removal or inhibition of CLK1.
3.4. Improved CLK1 inhibitors
The CLK1 inhibitors that performed best in our assays, NIH39 and
KH-CB19, had antiviral IC50 values of 6.6 μM and 13.6 μM, respec-
tively. In the search for a therapeutic intervention based on splicing
inhibition, we decided to further improve the compound efficacy. We
started a rational drug development program supported by (i) virtual
screening of inhibitor libraries, (ii) enzymatic screening using luci-
ferase- and LabChip-based assay systems and (iii) screening of selected
inhibitors regarding antiviral efficacy and cell viability.
We designed a library of 580 compounds by docking based on the
molecular structure of the hits and by docking of putative inhibitors
into the active site of the published CLK1 crystal structure (PDB-code
Fig. 2. Effect of CLK1 knockdown on influenza mRNA and protein levels. A549
cells were infected with influenza A/WSN/33 at MOI 4 for 5 h, at 48 h after
transfection with siRNA targeting CLK1 or non-targeting Allstars control siRNA.
(A) Ratio of spliced to unspliced mRNA upon CLK1 knockdown was calculated
by dividing the relative spliced mRNA level by the relative unspliced mRNA
level. Results represent mean ± SEM of three independent experiments; *p-
value< 0.05, two-tailed column statistics compared to the non-targeting
Allstars control. (B) The influenza M1, M2 and NS1 protein levels upon CLK1
knockdown were examined using Western Blot. Depicted immunoblots are re-
presentative of three independent experiments.
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Fig. 3. Screening of CLK inhibitors affecting influenza virus replication (A) A549 cells were treated with eight serial dilutions of the inhibitor dissolved in DMSO. Two
h later, cells were infected with A/WSN/33 at MOI of 0.0095 for 40 h. Infectious viral particles produced in the presence of the inhibitor were quantified using
indirect immunofluorescence staining and calculated as normalized percentage of infection from three independent experiments. (B,C) IC50 curve of NIH39 (B) and
KH-CB19 (C) activity on influenza virus replication, as well as the effect of inhibitor treatment on A549 cell viability (red lines). Data represent mean ± SEM of at
least three independent experiments. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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2VAG) (Fedorov et al., 2011). For docking simulations, the Schrödinger
Suite (https://www.schrodinger.com) was used. The compounds were
tested against CLK1 in a luciferase-based assay using recombinant CLK1
expressed in E. coli, and 56 compounds were found to be effective
(Supplementary Table 3). These results were further validated using a
capillary electrophoresis LabChip-based enzyme activity/phosphoryla-
tion assay capable of determining the IC50 concentration of each sub-
stance (Supplementary Table 3). Selected compounds with IC50 va-
lues < 1 μM were then analyzed by virus replication assay in
A549 cells to determine antiviral efficacy. We identified two com-
pounds, VCC080174 and VCC463764, which efficiently inhibited
influenza virus replication at very low concentrations (< 1 μM) and
revealed a promising therapeutic index (Fig. 7A and B).
VCC463764 and VCC080174 were then characterized by crystal-
lography to enable further optimization of the chemical structure for
maximum effectiveness against CLK1. Solving the crystal structures of
CLK1 in complex with VCC080174 to the resolutions of 2.03 Å confirms
that the inhibitor is localized within the ATP binding pocket, giving it
high efficiency against CLK1 (Fig. 7C). VCC463764 was also found to
bind CLK1 at the same binding pocket (data not shown). VCC080174
interacts with CLK1 at the active site by means of several hydrogen
bonds (Fig. 7D). The amino group connecting both six-membered rings
Fig. 4. NIH39 and KH-CB19 treatment lead
to changes in influenza mRNA splicing and
protein expression. (A,C) Ratio of viral
spliced to unspliced mRNA upon treatment
with NIH39 (A) or KH-CB-19 (B). A549 cells
were pre-treated with inhibitors or di-
methylsulphoxide (DMSO) for 2 h and sub-
sequently infected with influenza A/WSN/
33 at MOI 4 for 5 h. Results represent
mean ± SEM of at least three independent
experiments; *p-value<0.05, two-tailed
column statistics compared to the DMSO
control. (B,D) Influenza M and NS1 protein
expression upon treatment of A549 cells
using NIH39 (B) or KH-CB19 (D) with in-
fluenza A/WSN/33 infection at MOI 4 for
5 h. Immunoblots are representative of
three independent experiments.
Fig. 5. Treatment with CLK inhibitors alters
the consequence of CLK overexpression on
SRSF2 (SC35) subcellular distribution.
A549 cells were transfected with mCLK-GFP
plasmid overnight and then left untreated
or treated with 50 μM TG003, 12.5 μM
NIH39 or 50 μM kH-CB19 for 6 h. Cells were
stained with anti-SC35 antibody and after-
wards with Cy3-conjugated goat anti-mouse
IgG. Images shown are representative sam-
ples of the CLKs and SRSF2 localization
pattern from three independent experi-
ments. Fig. S6 provides the quantification of
cells showing speckled and non-speckled
patterns upon SC35 staining.
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of the inhibitor forms a hydrogen bond with the backbone oxygen atom
of Leu 244, whereas the nitrogen acceptor atom in the pyrimidine ring
is in close contact to the backbone nitrogen. Further, the thiazole amino
group is involved in a hydrogen bond to the Asp 325 carboxyl group.
This finding differs from other CLK1 complex structures such as the one
with KH-CB19 (PDB code 2vag) showing a different side chain con-
formation of Asp 325 that enables a hydrogen bond between the car-
boxylic group of Asp 325 and Gly 327 nitrogen. Similarly, in the iso-
forms CLK2, CLK3 and CLK4 hydrogen bonds between the
corresponding Asp and Gly exist (PDB codes 6fyi, 6fyp, 6fyv). A su-
perposition of the isoform structures suggests that VCC080174 may
show a similar hydrogen bond pattern in complexes with other mem-
bers of the CLK family. In CLK1, Leu 246 is located close to the
VCC080174 benzene ring, while in CLK3 this residue corresponds to Lys
241 (PDB code 6fyp). There is no change in CLK2 and CLK4. Further,
Val 324 corresponds to Ala 319 in CLK3 whereas there is no substitu-
tion in CLK2 and CLK4. Thus, hydrophobic interactions with the thia-
zole group might be different in CLK3 (Kallen et al., 2018). The simi-
larity of the CLK binding pockets and the identity of key residues,
however, suggest that it is difficult to obtain selective inhibitors binding
to this site, in particular for CLK1, CLK2 and CLK4.
Substitutions and extensions of the inhibitor structure may enable
the targeting of residues that vary between different CLK isoforms. For
example, the side chain of Ser 247 is located close to the inhibitor
VCC080174 in the CLK1 complex structure. This residue corresponds to
Asn 242 in CLK3. Further, Asp 250, corresponding to Glu 245 of CLK3,
is located at a suitable distance from the inhibitor. Differential targeting
of such isoform-specific key residues may be utilized to optimize in-
hibitor selectivity during lead optimization.
We then used a cell-based IAV-driven splicing assay that monitors
splicing from a viral-like mRNA derived from the M segment to analyze
the ratio of viral M1 to M2 mRNA after treatment of HEK293 cells with
the two CLK1 inhibitors, using the H3N2 (A/Victoria/3/75) seasonal
influenza virus strain. VCC080174 increased the ratio of spliced to
unspliced viral M mRNA (Fig. 7E), similar to the effect observed after
inhibition of CLK1 by siRNAs (see Fig. 2A). VCC463764, however, re-
duced the ratio of spliced to unspliced viral mRNA (Fig. 7D), as was
observed with the other chemical inhibitors (see Fig. 4A, C). Despite
this, VCC463764 nevertheless impaired virus replication, which sug-
gests that changes in the splicing ratio per se are detrimental to the
virus.
4. Discussion
Splicing factors are one of the enriched essential host factors for
influenza virus replication identified in several genome-wide screens
(Karlas et al., 2010; Konig et al., 2010; Watanabe et al., 2010). In the
screens performed in our lab (Karlas et al., 2016) and by König et al.
(2010) CLK1 (Colwill et al., 1996; Prasad et al., 1999), but no other
kinases known to regulate splicing, was identified as an essential host
factor. Here, we confirm that CLK1 is required for successful IAV re-
plication in vitro and in vivo, while the other CLK isoforms are not.
We previously found that the CLK inhibitor TG003 inhibits the re-
plication of IAV (Karlas et al., 2010). Based on this initial result, newly
developed CLK inhibitors were screened for their effectiveness against
IAV replication. Two of the most effective ones, NIH39 and KH-CB19,
were further assessed for their effect on influenza mRNA splicing. Only
NIH39 enhanced splicing, while KH-CB19 appeared to inhibit splicing.
In addition, viral M and NS mRNAs were affected differently. Regula-
tion of alternative splicing is influenced by CLK-mediated phosphor-
ylation of SR proteins. To date, it remains unknown which of the 9 SR
proteins are phosphorylated by which of the 4 CLK proteins. Thus, CLK1
might affect the splicing of M and NS mRNA via different phosphor-
ylation status of several SR proteins. We made the same observation
when testing two further compounds with enhanced effectiveness
against CLK1. Previous reports have shown differential effects of CLK
inhibitors towards different CLK isoforms (Muraki et al., 2004; Wong
et al., 2011), although the differential role of each isoform remains
Fig. 6. Identification of downstream targets
of CLK1 in correlation with influenza re-
plication inhibition. (A) Two different
siRNAs per gene were transfected to
A549 cells in 384-well plate format.
Replication assay was performed 48 h post
transfection by infecting cells with influenza
A/WSN/33 (MOI 0.014) for 40 h. Infectious
viral particles in the supernatants of infected
cells were quantified as PFU/ml. Data re-
present mean ± SD of three independent
experiments. (B, C) A549 cells were trans-
fected with siRNA targeting SRSF3 or
Allstars control in 12-well plate. After 48 h,
cells were infected with influenza A/WSN/
33 at MOI 4 for 5 h. (B) The ratio of spliced
(M2 and NS2, respectively) to unspliced
mRNA was calculated by dividing the re-
lative spliced mRNA level by the relative
unspliced mRNA level. Results represent
mean ± SEM of three independent experi-
ments; *p-value<0.05, two-tailed column
statistics compared to hypothetical value 1.
(C) The influenza M1, M2 and NS1 protein
levels upon SRSF3 knockdown were ex-
amined using Western Blot. Depicted im-
munoblots are representative of three in-
dependent experiments.
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unclear. Using the subnuclear distribution of SRSF2/SC35 as a read-out,
TG003, which effectively inhibits IAV replication, was shown to reverse
the effect of CLK1, 2 and 4 overexpression on SC35 subnuclear dis-
tribution (Wong et al., 2011, 2013). Here we observed that KH-CB19
was only able to reverse the effect of CLK4 overexpression, while NIH39
showed specificity towards CLK1 and 4. This may explain why NIH39
increases the ratio of spliced to unspliced influenza mRNA in a similar
manner to CLK1 knockdown, while KH-CB19 does not. It has been re-
ported before that thermal shift assay experiments with KH-CB19 using
different kinases showed the highest temperature shift for CLK4, fol-
lowed by CLK1 (Fedorov et al., 2011). Meanwhile, the same experiment
performed for NIH39 showed the highest temperature shift for CLK1,
followed by CLK2 and CLK4 (personal communication). The differences
of inhibitor specificity, determined either by using CLK proteins in the
thermal shift assay or by using cell based assays as shown in Fig. 5,
might be the reason for the different effects on influenza mRNA spli-
cing. These data also suggest that a specific inhibition of CLK1 is re-
quired to alter influenza M mRNA splicing. At the same time, CLK in-
hibitors with a lower affinity to CLK1, but specific for the other CLK
isoforms, strongly reduced viral protein expression from both spliced
and unspliced mRNA, thus indicating an additional effect on viral
mRNA export or translation, most likely via downstream effects on SR
proteins, which also play a role in mRNA export. Several SR proteins,
e.g. SRSF1, SRSF7 and SRSF3, can also shuttle between nucleus and
cytoplasm and interact with the export factor NXF1 (Caceres et al.,
1998; Huang et al., 2004). Remarkably, the biological functions of SR
are mainly regulated by distinct phosphorylation states (Botti et al.,
2017). Thereby, hyperphosphorylation of SR proteins by CLKs leads to
recruitment to transcription sites and spliceosome assembly, whereas
the PP1/2A phosphatases-mediated dephosphorylation during splicing
causes the release of the splicing machinery and supports the recruit-
ment of NXF1 and thus the export of mature mRNAs (Zhou and Fu,
2013).
Knocking down SR proteins revealed that SRSF3, and to a lesser
degree SRSF2 and SRSF5, are essential for influenza infection. The ef-
fects of SRSF3 knockdown on IAV mRNA splicing resembled those of
CLK1 knockdown. None of these factors have been reported to be in-
volved in influenza infection before, except for co-localization of SRSF2
with the NS1 protein of influenza B virus (Schneider et al., 2009). In-
terestingly, SRSF1 (SF2/ASF) knockdown only caused a minor reduc-
tion of IAV replication, despite the fact that SRSF1 has been shown to
bind M mRNA at the 3′ exon and regulate its splicing (Shih and Krug,
Fig. 7. Dose-response curves performed on A549 cells
pre-treated for 2 h with either VCC080174 (A) or
VCC463764 (B) and then infected with influenza A virus
(A/WSN/33) at MOI 0.01. Cells were further cultivated
for 36 h in the presence of these compounds. Red lines
indicate cell viability while black lines show reduction
in infection level. EC50(VCC080174) = 0.32 μM,
CC50(VCC080174) = 1.0 μM, selectivity index
(VCC080174) = 3.1, EC50(VCC463764) = 0.08 μM,
CC50(VCC463764) = 20.2 μM, selectivity index
(VCC463764) = 252.5 (C) Crystal structure of CLK1
(the N- and C-lobes are shown in yellow and cyan re-
spectively) in complex with VCC080174 (surface pre-
sentation). (D) The close-up shows the hydrogen
bonding network between the inhibitor and CLK1 at the
binding site (dashed lines). Nitrogen, oxygen and sul-
phur atoms are plotted in blue, red and yellow, re-
spectively. (E) The influence of VCC080174 or
VCC463764 on the splicing of the viral matrix gene
segment (M). The splicing rates were analyzed using a
dual luciferase assay where Renilla luciferase monitors
the unspliced M1 expression levels, and Firefly luci-
ferase indicates M2 expression. The expression of the
luciferase reporters was induced by co-infection with the
seasonal H3N2 influenza virus strain (A/Victoria/3/75).
Results represent mean + SD. (For interpretation of the
references to colour in this figure legend, the reader is
referred to the Web version of this article.)
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1996). This does not exclude the possibility that other SR proteins
might also regulate M mRNA splicing. SRSF1 has recently also been
shown to bind to NS mRNA (Huang et al., 2017), but the interaction of
other SR proteins with influenza mRNA sequences and their impact on
virus replication still need to be investigated. Also, we cannot rule out
that a change in splicing preferences after CLK1 inhibition may lead to
an alteration in the global cellular protein composition that could affect
influenza virus replication indirectly.
In summary, CLK1 downregulation impairs IAV replication by al-
tering viral mRNA splicing and viral protein expression, most likely via
differential effects on SR proteins. For regulation of host cell processes,
different CLK isoforms are likely to exhibit some functional re-
dundancy, as no dramatic phenotypical defect was observed in the
CLK1 knockout mice. Therefore, CLK1 represents a potential new host-
directed target for influenza therapy. By following this rational drug
development program, we were already able to greatly improve the
efficacy of the CLK1 inhibitors. The next step will be to characterize the
ADME profile of these compounds in detail and examine their efficacy
against influenza virus infection in animal models.
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